Clinical trial • Phase IV • Other
Ferrous sulfate for Iron deficiency
Phase IV trial of Ferrous sulfate for Iron deficiency.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Iron deficiency
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
- Paediatric Trial
- Yes
Key dates
- Initial CTIS Submission Date
- 13-02-2026
- First CTIS Authorization Date
- 14-04-2026
Trial design
Randomised, active intervention: duroferon 100 mg administered on alternate days in combination with iron smart. comparator arm: duroferon placebo plus iron smart (placebo arm).-controlled Phase IV trial in Sweden.
- Randomised
- Yes
- Comparator
- Active intervention: Duroferon 100 mg administered on alternate days in combination with Iron Smart. Comparator arm: Duroferon placebo plus Iron Smart (placebo arm).
- Target Sample Size
- 279
Eligibility
Recruits 279 paediatric patients.
- Pregnancy Exclusion
- Pregnancy
- Vulnerable Population
- Participants are adolescent girls (includes minors). Written informed consent is required from the participant; written informed consent from legal guardian(s) is required if the participant is <18 years. A re-consent procedure at 18 years is documented (L1_Re-consent_18 years).
Inclusion criteria
- {"criterion_text":"- Student at Polhemskolan, Lund\n- Age ≥15 years\n- Post-menarcheal\n- Written informed consent from the participant\n- Written informed consent from legal guardian(s) if <18 years\n- Serum ferritin <30 µg/L"}
Exclusion criteria
- {"criterion_text":"- Pregnancy\n- Chronic inflammatory disease (e.g. rheumatoid arthritis, Crohn’s disease)\n- Ongoing acute infection (e.g. tonsillitis, urinary tract infection)\n- CRP >10 mg/L\n- Current iron supplementation (except multivitamins)\n- Anaemia (Hb <110 g/L if <18 years; <117 g/L if ≥18 years, according to regional reference limits)\n- Iron overload (serum ferritin >150 µg/L; WHO definition)\n- Clinically significant vitamin B12 deficiency requiring immediate medical evaluation or treatment (e.g. serum vitamin B12 <150 pmol/L).\n- Use of medication known to interfere with iron absorption or cause clinically significant interaction with oral iron (e.g. fluoroquinolones, tetracyclines, bisphosphonates, levodopa, methyldopa, aluminium- or magnesium-containing antacids), defined as regular or daily use (≥3 times per week)."}
Endpoints
Primary endpoints
- {"endpoint_text":"- 1. Feasibility, including recruitment, retention, adherence and tolerability.\n- 2. Diagnostic performance of IRON-5 (sensitivity, specificity, positive and negative predictive values, and ROC-AUC).","definition_or_measurement_approach":"Feasibility measured by recruitment, retention, adherence and tolerability metrics. Diagnostic performance of IRON-5 measured by sensitivity, specificity, positive and negative predictive values and ROC-AUC versus ferritin-defined iron deficiency (ferritin <15 µg/L)."}
Secondary endpoints
- {"endpoint_text":"- Change in ferritin concentration.\n- Change in haemoglobin, TSAT, vitamin B12 and 25-hydroxyvitamin D from screening to follow-up.\n- Associations between iron deficiency and selected factors (dietary patterns, BMI, menstrual characteristics including bleeding volume, menstrual pain and analgesic use, hormonal contraceptive use, physical activity, socioeconomic status and country of birth).\n- Associations between fatigue and self-rated QoL and factors other than iron deficiency (e.g. vitamin B12 and vitamin D deficiency, anxiety/depression and lifestyle factors).","definition_or_measurement_approach":"Change endpoints assessed from screening to follow-up for laboratory measures (ferritin, haemoglobin, TSAT, vitamin B12, 25-hydroxyvitamin D). Association endpoints explored using collected questionnaire and clinical data (dietary patterns, BMI, menstrual characteristics, physical activity, socioeconomic status, country of birth, fatigue and QoL measures)."}
Recruitment
- Digital Remote Recruitment
- Yes
- Planned Sample Size
- 279
- Recruitment Window Months
- 9
- Consent Approach
- Written informed consent from the participant is required. For participants <18 years, written informed consent from legal guardian(s) is required. A re-consent process at 18 years is documented (L1_Re-consent_18 years). Participant information and consent forms are provided (documents L1_SIS_trial participant and L1_SIS_Legal_guardian). Languages available are not specified in the record.
Methods
- School-based recruitment: inclusion criterion specifies 'Student at Polhemskolan, Lund' indicating recruitment at Polhemskolan, Lund (Sweden).
- Recruitment materials: recruitment poster and other recruitment materials (document titles include 'K2_Recruitment poster_DRAFT_IRONGIRLS-PILOT' and 'K2_Beskrivning av rekryteringsmaterial_IRONGIRLS-PILOT').
- Digital/app-related: use of the Iron Smart app (document 'L2_Beskrivning av Iron Smart-appen') as part of the study/intervention and recruitment information.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 279
Sweden
- Earliest CTIS Part Ii Submission Date
- 01-04-2026
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 13
- Number Of Sites
- 1
- Number Of Participants
- 279
Sites
- Site Name
- Region Skane
- Department Name
- Center for Primary Health Care Research, Nöbbelöv Primary Health Care Center, 22638 Lund
- Contact Person Name
- Moa Wolff
- Contact Person Email
- irongirls@med.lu.se
Sponsor
Primary sponsor
- Full Name
- Region Skane
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- Duroferon depottabletter
- Active Substance
- Ferrous sulfate
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- oral
- Authorisation Status
- Authorised (marketingAuthNumber: 5680; authorisationCountryCode: NO)
- Starting Dose
- 100 mg
- Dose Levels
- 100 mg
- Frequency
- Alternate days
- Maximum Dose
- 100 mg
- Investigational Product Name
- Duroferon placebo
- Modality
- Other
- Authorisation Status
- No marketing authorisation (marketingAuthNumber: N/A; authorisationCountryCode: IS)
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.